Abstract: The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention are produced 5 by inserting one or more foreign genes into IL-18 binding protein (IL18bp) gene of swinepox virus. The invention is particularly suited to produce swine vaccines, particularly for vaccinating swine against PCV2 infection.

Abstract: The invention relates to a composition containing pheromones comprising a carrier solvent, and to the use thereof for preventing and/or treating the behavioral or medical problems linked to the stress of non-human mammals. The invention also relates to a device for diffusing such a composition into the ambient air, and to a kit comprising said composition.

Abstract: This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to have been infested with filarioid nematodes such as Dirofilaria spp, an effective dose of a combination of a neonicotinoid compound and a pyrethroid compound.

Abstract: The invention relates to novel veterinary compositions comprising an effective amount of a neonicotinoid compound and an effective amount of a N-arylpyrazole compound. The invention also relates to the use of such compositions for controlling ectoparasites in a non-human mammal.

Abstract: The invention relates to improved methods for protecting non-human animals with triazine compounds by intramuscular or subcutaneous injection(s). The invention can be used with various triazines, such as toltrazuril, in different non-human animals, such as a porcine, an ovine, a bovine, a canine, a feline, or an avian, for protecting them against infectious diseases, such as protozoan disorders.

Abstract: The present invention relates to a parenteral composition comprising an antibiotic and a non-steroidal anti-inflammatory agent in solution in a particular solvent. The composition is intended in particular to be injected in a non-human mammal, in particular a farm animal. It also relates to a method for treating disorders connected with a microbial infection in non-human mammals by injecting said composition.

Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.

Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for promoting a substantial reduction of lactation, mammary involution, and for treating and/or intra-mammary diseases or infections of ruminants.

Abstract: The present invention relates to novel compositions for inducing an immune response in mammals. The composition preferably comprises an antigen and a lipopolysaccharide in an oil-in-water formulation. The invention is particularly suited to vaccinate swine against mycoplasma infections.

Abstract: The invention relates to compositions and to the methods of administration thereof. More specifically, it relates to an optimised method for the administration of active agents to non-human mammals by means of topical application of pre-determined doses.

Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.

Abstract: The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.

Abstract: The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions.

Abstract: The invention relates to a liquid pharmaceutical composition, in the form of a suspension of micronized powder of active substance in an acceptable physiological liquid medium, stabilized over time, for administration via the oral route.

Abstract: Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration.

Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.

Abstract: Multi-layered plastic polymeric container useful for the storage and conservation of pharmaceutical compositions, sterile or non sterile, which comprises an inner layer and an outer layer, a gas barrier layer, and adhesive layers.

Abstract: The present invention relates to the novel Porcine Circovirus type 2 subtype B (PCV2B-Rm) isolate which comprises a short duplication of sequence and is adapted to grow in cell culture and may be propagated at high titres constantly up to 106 TCID50 viral particles per mL. This novel isolate is particularly useful for the production of porcine circovirus type 2 (PCV2) vaccines, for treating and/or preventing and/or diagnosing porcine circovirus associated diseases, as well as for diagnosing the presence of porcine circovirus in pigs. The present invention also relates to novel cell clones derived from Swine Testicles (ST) useful for propagating PCV2 and to a method for production of PCV2 virus with particularly high titers.